I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ESMO-ASIA SINGAPORE, SINGAPORE, 23–25 NOVEMBER 2018

Afatinib followed by osimertinib in real-world patients with EGFR mutation-positive NSCLC: an observational study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A. Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer

RELATED MATERIALS

Learn more about the science behind this poster in the videos, papers and other materials below.

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

V. Hirsh. Ther Adv Med Oncol. 10(1), 1758834017753338 (2018)

Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer

T. S. Mok, Y. L. Wu, M. J. Ahn, et al. N Engl J Med. 376(7), 629-640 (2017)

FOR HEALTHCARE PROFESSIONALS ONLY.

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

 

image